Group 1 - Pagaya Technologies Ltd. (PGY) closed at $14.96, with a 49.8% gain over the past four weeks, and a mean price target of $22.69 suggests a 51.7% upside potential [1] - The average price targets from analysts range from a low of $13.75 to a high of $36, with a standard deviation of $7.04, indicating variability in estimates [2] - Analysts show strong agreement on PGY's ability to report better earnings, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for PGY's current year earnings has increased by 2.8% over the last 30 days, with no negative revisions [12] - PGY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [13]

Group 1 - Xperi (XPER) has shown a significant price increase of 27.7% over the past four weeks, with a mean price target of $18.25 indicating an upside potential of 118.8% [1] - The average price target ranges from a low of $12 to a high of $30, with a standard deviation of $8.02, suggesting variability in analysts' estimates [2] - The consensus price target is not the sole metric for investment decisions, as analysts' ability to set accurate price targets has been questioned [3] Group 2 - Strong agreement among analysts regarding XPER's earnings prospects, indicated by positive earnings estimate revisions, supports the expectation of stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for XPER's current year earnings has increased by 46.2%, with no negative revisions [12] - XPER holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]

Core Viewpoint - Zymeworks Inc. (ZYME) shows significant potential for upside, with a mean price target of $21.35 indicating an 83.9% increase from the current price of $11.61 [1] Price Targets and Analyst Consensus - The average of 10 short-term price targets ranges from a low of $12 to a high of $30, with a standard deviation of $7.45, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 3.4% increase, while the highest suggests a 158.4% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising ZYME's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.6%, with two estimates moving higher and no negative revisions [12] - ZYME holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][7] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism [10]

Sangoma Technologies Corporation (SANG) closed the last trading session at $5.95, gaining 29.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.36 indicates a 40.5% upside potential.The average comprises four short-term price targets ranging from a low of $7.94 to a high of $9.50, with a standard deviation of $0.76. While the lowest estimate indicates an increase of 33.5% from t ...

Core Viewpoint - Crexendo (CXDO) has shown a significant price increase of 24.2% over the past four weeks, with analysts suggesting further upside potential based on a mean price target of $8.30, indicating a 42.9% increase from the current price of $5.81 [1] Price Targets and Analyst Estimates - The mean price target consists of five short-term estimates with a standard deviation of $0.97, where the lowest estimate is $7.50 (29.1% increase) and the highest is $10 (72.1% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about CXDO's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, two earnings estimates have been revised upward, leading to an 18.2% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - CXDO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]

uniQure (QURE) closed the last trading session at $12.81, gaining 32.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $33.50 indicates a 161.5% upside potential.The average comprises 10 short-term price targets ranging from a low of $20 to a high of $70, with a standard deviation of $15.33. While the lowest estimate indicates an increase of 56.1% from the current price level, the ...

Core Viewpoint - BioLife Solutions, Inc. (BLFS) shares have increased by 8.2% recently, with a mean price target of $31.22 suggesting a potential upside of 30.7% from the current price of $23.89 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $1.48, indicating variability among analysts [2] - The lowest price target is $30, representing a 25.6% increase, while the highest target is $34, indicating a potential surge of 42.3% [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about BLFS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has risen by 19.2% over the past month, with no negative revisions [12] - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]

Shares of AudioEye (AEYE) have gained 14.3% over the past four weeks to close the last trading session at $12.90, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.40 indicates a potential upside of 73.6%.The mean estimate comprises five short-term price targets with a standard deviation of $2.51. While the lowest estimate of $20 indicates a 55% increase from the current price ...

Shares of Beyond (BYON) have gained 30.8% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.83 indicates a potential upside of 156.1%.The mean estimate comprises six short-term price targets with a standard deviation of $12.16. While the lowest estimate of $5 indicates a 0.2% decline from the current price le ...

Clearfield (CLFD) closed the last trading session at $36.36, gaining 37.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $46 indicates a 26.5% upside potential.The average comprises four short-term price targets ranging from a low of $44 to a high of $50, with a standard deviation of $2.71. While the lowest estimate indicates an increase of 21% from the current price level, the m ...